A GnRH Antagonist under Clinical Development for Endometriosis
Endometriosis is a condition in which the layer of tissue that normally covers the inside of the uterus, grows outside on the ovaries, fallopian tubes, tissues around the uterus and ovaries, or other parts of the body.
Gonadotropin-releasing hormone antagonists (GnRH antagonists) could bind to GnRH receptor, and thus inhibit the synthesis and release of gonadotropins, and therefore decrease the levels of estrogens and androgens. GnRH antagonists are developed to treat endometriosis and fibroids.
SHR7280 is an oral GnRH antagonist to address endometriosis. A phase I clinical trial is ongoing in China.